Search

Your search keyword '"Lee, Kwangho"' showing total 372 results

Search Constraints

Start Over You searched for: Author "Lee, Kwangho" Remove constraint Author: "Lee, Kwangho" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
372 results on '"Lee, Kwangho"'

Search Results

1. Chupa: Carving 3D Clothed Humans from Skinned Shape Priors using 2D Diffusion Probabilistic Models

2. LPMM: Intuitive Pose Control for Neural Talking-Head Model via Landmark-Parameter Morphable Model

3. Cross-Domain Style Mixing for Face Cartoonization

5. Investigating Language Learning Strategies in English Conversation Using Non-Hierarchical Cluster Analysis

7. Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2).

8. Genomic Analysis and Tracking of SARS‐CoV‐2 Variants in Gwangju, South Korea, From 2020 to 2022.

14. Re-Emergence of HMPV in Gwangju, South Korea, after the COVID-19 Pandemic

20. Re-emergence of HMPV in Gwangju, South Korea, After the COVID-19 Pandemic: Impact on Subtypes and Age Distribution

24. Abstract 4029: JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC

25. Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

26. Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

27. Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

28. Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

29. Data from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

30. Supplementary Materials and Methods from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

31. Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

32. Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

33. Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

34. Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

35. Supplementary Table 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

36. Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

37. Supplementary Materials and Methods and Supplementary Figure Legends from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

38. Supplementary Figure 4 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

39. Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

40. Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

44. Discovery of TRD‐93 as a novel DRAK2 inhibitor

48. Venous outflow-targeted coil embolization of direct carotid-cavernous fistulas.

Catalog

Books, media, physical & digital resources